Silexion Therapeutics Corp received an amended Schedule 13G reporting that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 325,000 ordinary shares, or about 9.4% of the company, as of December 31, 2025.
The reported position consists entirely of warrants held by Intracoastal Capital LLC, which are exercisable into 325,000 ordinary shares through two separate warrants of 162,500 shares each. All voting and dispositive power over these shares is shared among the reporting persons, with no sole voting or dispositive authority.
An additional 32,100 shares underlying a third warrant are excluded because that warrant has a 4.99% beneficial ownership blocker, which limits exercises that would push the group’s ownership above that threshold.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Silexion Therapeutics Corp
(Name of Issuer)
Ordinary shares, par value $0.0135 per share
(Title of Class of Securities)
G1281K130
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
G1281K130
1
Names of Reporting Persons
Mitchell P. Kopin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
325,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
325,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
325,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
G1281K130
1
Names of Reporting Persons
Daniel B. Asher
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
325,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
325,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
325,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
G1281K130
1
Names of Reporting Persons
Intracoastal Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
325,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
325,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
325,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Silexion Therapeutics Corp
(b)
Address of issuer's principal executive offices:
12 Abba Hillel Road, Ramat-Gan, Israel 5250606
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)
Address or principal business office or, if none, residence:
The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)
Citizenship:
Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)
Title of class of securities:
Ordinary shares, par value $0.0135 per share
(e)
CUSIP No.:
G1281K130
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on December 31, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 325,000 Ordinary Shares, which consisted of (i) 162,500 Ordinary Shares issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1")and (ii) 162,500 Ordinary Shares issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2"), and all such Ordinary Shares represent beneficial ownership of approximately 9.4% of the Ordinary Shares, based on (1) 3,126,642 Ordinary Shares outstanding as of November 9, 2025, as reported by the Issuer, plus (2) 162,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 and (3) 162,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 32,100 Ordinary Shares issuable upon exercise of a third warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 357,100 Ordinary Shares.
(b)
Percent of class:
9.4 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
325,000
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
325,000
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What ownership stake in Silexion Therapeutics Corp (SLXN) is reported in this Schedule 13G/A?
The filing reports beneficial ownership of 325,000 ordinary shares of Silexion Therapeutics Corp, representing about 9.4% of the outstanding ordinary shares. This stake is held through warrants and reflects the group status of the reporting persons.
Who are the reporting persons in the Silexion Therapeutics Corp (SLXN) Schedule 13G/A?
The Schedule 13G/A is filed on behalf of Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. Kopin and Asher are U.S. individuals, while Intracoastal is a Delaware limited liability company holding the warrants.
How is the 9.4% beneficial ownership in Silexion (SLXN) calculated in the filing?
The 9.4% is based on 3,126,642 ordinary shares outstanding as of November 9, 2025, plus 325,000 shares underlying two Intracoastal warrants. This combined figure forms the denominator used to compute the reported ownership percentage.
What securities do the reporting persons hold in Silexion Therapeutics Corp (SLXN)?
Their reported position consists of 325,000 ordinary shares issuable upon exercise of two Intracoastal warrants, each for 162,500 shares. They report no currently outstanding shares held outright, only these warrant-based rights to acquire shares.
Why are 32,100 additional Silexion (SLXN) shares excluded from the reported ownership?
The filing excludes 32,100 shares underlying a third Intracoastal warrant because it includes a 4.99% beneficial ownership blocker. This provision prevents exercises that would raise the holder’s beneficial ownership above 4.99% of Silexion’s ordinary shares.
Do the reporting persons seek to influence control of Silexion Therapeutics Corp (SLXN)?
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Silexion Therapeutics Corp, and are not part of any transaction designed to have that effect, other than limited nomination-related activities.
